Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug977 | Collection of breath sample Wiki | 0.33 |
| drug2764 | PF-06882961 20MG Wiki | 0.33 |
| drug3119 | Prospective Chart Review Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001392 | Abnormality of the liver HPO | 1.00 |
| HP:0000819 | Diabetes mellitus HPO | 0.06 |
Navigate: Correlations HPO
There are 9 clinical trials
The purpose of this study is to characterize the single-dose plasma PK of mobocertinib and its active metabolites (AP32960 and AP32914) in participants with moderate and/or severe HI compared to matched-healthy participants with normal hepatic function.
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
Description: Analysis of profiles of volatile organic compounds present in exhaled breath
Measure: Breath volatile organic compound profiles Time: 1 dayDescription: Diagnosis or prognostic utility of breath volatile organic compound profiles
Measure: Utility of breath profiles for disease diagnosis or prognosis Time: 14 daysThe current outbreak of COVID-19 pandemic has been marked by severe psychological problems. People around the world experienced a similarly frightening public health emergency, on a global scale, with the spread of this corona infection. (1) Studies of the Severe Acute Respiratory Syndrome (SARS) outbreaks that occurred in Canada, Taiwan, and Hong Kong found that the enormous emotional burden carried by those health care workers who were on the front lines of the battle against the disease led to psychological morbidity like anxiety, stress and even further leads to Post traumatic stress disorder. The initial phase of the COVID-19 outbreak in China in 2020 also reported more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety in general population.(2) - The chances of Fear, anxiety and stress are even higher in Individuals with preexisting liver disease as they have restriction of services for getting treatment. Moreover, they can have the following additional issues: - Fear of severe form of Corona present (as presented in most of the media and research) - Fear of dying - Added uncertainty - Family members also worried
Description: Following questionnaire will be used For Fear of COVID-19: FEAR OF COVID-19 Scale Fear of Coronavirus-19 Scale: The participants indicate their level of agreement with the statements using a five-item Likert-type scale. Answers included "strongly disagree," "disagree," "neither agree nor disagree," "agree," and "strongly agree". The minimum score possible for each question is 1, and the maximum is 5. A total score is calculated by adding up each item score (ranging from 7 to 35). The higher the score, the greater the fear of cororonavirus-19.
Measure: Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For, anxiety: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Depression Anxiety Stress Scale (DASS)-21: The DASS-21 is based on three subscales of depression, stress, and anxiety and each subscale consists of seven questions each. Each subscale comprises of seven statements regarding how the test subject was feeling over the last week and four responses ranging from 0- did not apply to me at all, 1- applied to me some of the time, 2- applied to me for a considerable amount of time to 3- applied to me very much/most of the time. The scoring system is of the Likert type and the total score for each subscale gives the severity of that very symptom which has a range from 0 to 21 for each subscale.
Measure: Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o Stress levels: DASS - 21 Scale Depression Anxiety Stress Asymptomatic ≤4 ≤3 ≤7 Symptomatic >4 >3 >7
Measure: Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For Fear of COVID-19: FEAR OF COVID-19 Scale
Measure: Association between presence of Liver disease and fear levels Time: Day 0Description: Following questionnaire will be used o For, anxiety levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition
Measure: Association between presence of Liver disease and anxiety levels Time: Day 0Description: Following questionnaire will be used o For stress levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition.
Measure: Association between presence of Liver disease and stress levels Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between Fear and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between fear and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Model for End Stage Liver Disease Score Time: Day 0Background: The COVID19 and liver relationships are very rare. The preliminary Chinese data indicate that 2-11% of patients treated for COVID19 had an underlying chronic liver disease. However, there is no clinical data on morbi-mortality in this context. Objectives: Primary Objective: Evaluate the mortality related to Covid-19 in patients with a chronic liver disease Secondary objectives: - Evaluate the mortality (liver-related and no liver-related) due to the Covid-19 according to the cirrhotic status, an history of hepatocellular carcinoma, an immunosuppressive treatment and its type, the etiology-ies of liver disease at the diagnosis of Covid-19 (viral hepatitis -B and/or C-, liver disease related to alcohol consumption, metabolic syndrome, hemochromatosis, immune liver disease, other or unknown), and comorbidities - Evaluate the liver morbidity related to Covid-19, including - incidence of liver biochemical abnormalities in patients with normal liver enzymes values or of a 2-fold increase of usual values for AST, ALT, GGT, Alcalines Phosphatasis - incidence of liver complications (acute hepatitis, liver insufficiency, decompensation of cirrhosis, encephalopathy, renal insufficiency) Patients: All patients with a liver disease (chronic or acute) with a positive diagnosis of Covid-19 assessed either by positive PCR or specific thoracic abnormalities at TDM Methodology: Observational ambispective study consisting exclusively of a collection of data from patients with liver diseases and managed for COVID 19 The data is collected and transcribed on a secure electronic eCRF hosted at the Assitance Publique des Hôpitaux de Paris and accessible online from the AFEF website Duration and organisation of the research: After information of the patients and making available a non-opposition form, the main demographic and clinical data related to the liver disease and to the COVID19 already collected in the patient's medical record will be collected in a dedicated e-CRF. Effective of the study: All consecutive patients included in the study whose data are collected e-CRF until 31/12/2020.
Description: defined with liver biopsy or non invasive tests of fibrosis or according the opinion of clinician
Measure: mortality rate according the stage of fibrosis and the cirrhotic status Time: Up to 30 daysDescription: acute hepatitis, liver insufficiency, decompensation of cirrhosis, encephalopathy, renal insufficiency
Measure: Incidence of liver complications Time: through patient follow-up, an average of 1 yearThis is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus infection. Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally. A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care. Treatment duration: 21 days.
Description: The number of days required to achieve a score of 0 for each symptom category. Resolution of symptoms: fever (time frame: 21 days) Fever based on a 0-3 scale: 0 = ≤98.6, 1 => 98.6- 100.6, 2 => 100.6 - 102.6, 3 => 102.6 Resolution of symptoms: cough (time frame: 21 days) Cough based on a 0-3 scale: 0 = no cough, 1 = mild, 2 = moderate, 3 = severe Resolution of symptoms: shortness of breath (time frame: 21 days) Shortness of breath based on a 0-3 scale: 0 = no shortness of breath, 1 = with moderate intensity exercise 2 = walking on a flat surface 3 = shortness of breath when dressing or doing daily activities Resolution of symptoms: fatigue (period: 21 days) Fatigue based on a 0-3 scale: 1 = mild fatigue, 2 = moderate fatigue, 3 = severe fatigue. Composite score that includes all symptoms: (time frame: 21 days) Total composite score of symptoms on days 5, 10, 15, and 21 of study supplementation.
Measure: Symptom resolution Time: 21 daysDescription: Disease severity will be measured using a disease severity clinical event scale (assessed until day 21) Change from baseline in the patient's health status on an ordinal scale of 7 categories (time frame: days 3, 7, 14, 21) death Hospitalized, with invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, with non-invasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, which does not require supplemental oxygen Not hospitalized, limitation of activities. Not hospitalized, without limitations in activities. Note: lower scores mean a worse result.
Measure: Cumulative incidence of disease severity Time: 21 daysDescription: Differences in the number of patients who received complementary medications for diagnosis between the study arms.
Measure: Complementary drugs required Time: 21 daysDescription: Differences in the number of patients in the study groups experiencing side effects of the supplements.
Measure: Side effects of supplementation Time: 21 daysDescription: PCR analysis at day 0, 7th, 14th and 21th to measure and compare viral load
Measure: Duration of SARS-CoV-2 PCR positivity Time: 21 daysDescription: Blood biochemical analysis at day 0, 3rd, 7th, 14th and 21th
Measure: Concentration of reactive protein c in peripheral blood Time: 21 daysDescription: Number of Incidence of hospitalization
Measure: Incidence of hospitalization Time: 21 daysDescription: Number of days of hospitalization
Measure: Duration (days) of hospitalization Time: 21 daysDescription: Number of Incidences of mechanical ventilation supply per patient
Measure: Incidence of mechanical ventilation supply Time: 21 daysDescription: Number of days with mechanical ventilation supply
Measure: Duration (days) of mechanical ventilation supply Time: 21 daysDescription: Number of incidences of oxygen use
Measure: Incidence of oxygen use Time: 21 daysDescription: Number of days of oxygen use per patient
Measure: Duration (days) of oxygen use Time: 21 daysDescription: Number of death per group
Measure: Mortality rate Time: 21 daysDescription: Number of days patient need to recover from disease
Measure: Time to return to normal activity Time: 21 daysDescription: Change from baseline in serum cytokine IL-1 level by blood biochemical analysis at day 0, 3, 7, 14 and 21
Measure: Change from baseline in serum cytokine levels Time: 21 daysDescription: Change from baseline in serum cytokine IL-6 level by blood biochemical analysis at day 0, 3, 7, 14 and 21
Measure: Change from baseline in serum cytokine levels Time: 21 daysDescription: Change from baseline in serum cytokine TNF-α level by blood biochemical analysis at day 0, 3, 7, 14 and 21
Measure: Change from baseline in serum cytokine levels Time: 21 daysDescription: Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages by blood biochemical analysis at day 0, 3, 7, 14 and 21
Measure: Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages Time: 21 daysDescription: Change from baseline in CD3 +, CD4 + and CD8 + T cell counts by blood biochemical analysis at day 0, 3, 7, 14 and 21.
Measure: Change from baseline in CD3 +, CD4 + and CD8 + T cell counts Time: 21 daysDescription: Change in liver function test (AST, ALT and TBIL) by blood biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in liver function test Time: 21 daysDescription: Change in kidney function with eGFR rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in kidney function test Time: 21 daysDescription: Change in kidney function with creatine clearance rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in kidney function test Time: 21 daysDescription: Change in routine blood test red blood cells concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in routine blood test Time: 21 daysDescription: Change in routine blood test white blood cell concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in routine blood test Time: 21 daysDescription: Change in routine blood test D-dimer level by blood biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in routine blood test Time: 21 daysDescription: Change in routine blood test fibrinogen level by blood biochemical analysis at day 0, 4, 7, 14 and 21.
Measure: Change in routine blood test Time: 21 daysDescription: Change in myocardial enzyme CPK-MB by blood biochemical analysis at daty 0, 4, 7, 14 and 21
Measure: Change in myocardial enzymes Time: 21 daysDescription: Change in myocardial enzymes troponins by blood biochemical analysis at daty 0, 4, 7, 14 and 21
Measure: Change in myocardial enzymes Time: 21 daysThis study aims primarily 1. to assess the frequency, nature and outcome of liver disease caused or associated with COVD-19 Furthermore, the study also aims 2. to assess the impact of COVID-19 on patients with chronic liver disease or after liver transplantation (frequency of infections, course of disease, outcome) 3. to assess, whether quarantine measures impact on the rate of decompensation of liver cirrhosis 4. to assess whether the intake of antiviral drugs protects against SARS-CoV-2 infection or COVID disease.
Description: elevated transaminases
Measure: liver disease Time: through study completion, on average 30 daysDescription: frequency of COVID infection in patients with known chronic liver disease
Measure: COVID infection in patients with chronic liver disease Time: during the pandemic, at longest until 31.12.2022Description: episodes of decompensation of cirrhosis in relation to quarantine measures
Measure: decompensation of cirrhosis Time: during the pandemic, at longest until 31.12.2022Description: frequency of infections in people taking antiviral drugs against hepatitis B or C
Measure: Effect of Antiviral drugs on Covid-19 infection Time: during the pandemic, at longest until 31.12.2022COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study. All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included
Description: To study the prevalence of liver live injury & factors associated with among patients in-fected with SARS-CoV-2.
Measure: COVID-19 Positive Case Time: 4-8 weeksDescription: To study the prevalence of new liver injury and factors associated with it, among patient with underlying liver disease who develops COVID-19.
Measure: COVID-19 Positive Case Time: 4-8 weeksDescription: To correlate the presence and degree of liver dysfunction with the clinical outcomes in these patients.
Measure: COVID-19 Positive Case Time: 4-8 weeksDescription: To define the incidence of development of acute liver failure among these patients
Measure: COVID-19 Positive Case Time: 4-8 weeksThis study seeks to determine how COVID-19 affects the clinical outcome of patients with chronic liver disease, and whether the clinical course of COVID-19 is influenced by underlying chronic liver disease.
Description: Death due to any cause
Measure: All-cause mortality Time: 30 daysDescription: Death due to any cause
Measure: All-cause mortality Time: 1 yearDescription: Death due to liver-related cause
Measure: Liver-related mortality Time: 28 daysDescription: Death due to liver-related cause
Measure: Liver-related mortality Time: 1 yearDescription: Patients will be assessed for this outcome for up to 1 year
Measure: Overall survival Time: Up to 1 yearDescription: Onset of hepatic decompensation due to COVID-19 disease; patients will be assessed for this outcome for up to 1 year
Measure: Number of patients with hepatic decompensation Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Number of patients requiring hospitalization Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Duration of hospitalization Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Length of intensive care unit (ICU) stay Time: Up to 1 yearDescription: Patients will be assessed for this outcome for up to 1 year.
Measure: Number of participants requiring mechanical ventilation Time: Up to 1 yearThe current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports